Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07676435 · ClinicalTrials.gov registry record · Phase 2
Ongoing Lung Decline With Age Intensified Response
A Phase 2 study, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT07676435 is a Phase 2 study that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 40 participants.
The verdict
NCT07676435, a Phase 2 study, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This Phase II, randomized, double-blind, placebo-controlled pilot study will evaluate the effects of fisetin, a senolytic flavonoid compound, on lung function and biomarkers of cellular senescence in older adults aged 60 years and older. Participants will include individuals with a history of at least 10 pack-years of smoking as well as age-matched never-smokers. Forty participants will be randomized to receive either fisetin or placebo using a short-course "hit-and-run" dosing strategy (approximately 20 mg/kg/day orally for 2 consecutive days on Days 1-2 and Days 8-9).
Interventions
- DRUG Placebo
- DRUG Fisetin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-06-17 |
| Est. Completion | 2027-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07676435
The ClinicalTrials.gov registry entry for NCT07676435 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07676435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07676435 about?
NCT07676435 is a clinical study titled "Ongoing Lung Decline With Age Intensified Response". This Phase II, randomized, double-blind, placebo-controlled pilot study will evaluate the effects of fisetin, a senolytic flavonoid compound, on lung function and biomarkers of cellular senescence in older adults aged 60 years and older. Participants will include individuals with a history of at lea...
What is the current status of trial NCT07676435?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2026-06-17. Estimated completion is 2027-07-15.
What interventions are being tested in trial NCT07676435?
The interventions under investigation include: Placebo (DRUG), Fisetin (DRUG).
Who is sponsoring clinical trial NCT07676435?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.